PacBio expands its partnership with seqWell to distribute the LongPlex™ Multiplexing Kit for efficient genomic sample preparation.
Quiver AI Summary
PacBio has announced an expanded partnership with seqWell to distribute the LongPlex™ Multiplexing Kit, which streamlines sample preparation for PacBio HiFi sequencing. This kit is designed to enhance efficiency in DNA fragmentation and multiplexing, enabling researchers to produce high-quality libraries quickly and cost-effectively. The collaboration aims to provide a flexible, high-throughput solution for various research applications such as low-pass whole genome sequencing and microbial sequencing. Major organizations like Veil Genomics are already utilizing LongPlex to facilitate large-scale genomic studies. The kit is available now, with plans for broader global distribution in 2026, reflecting a commitment to advance genomic research capabilities.
Potential Positives
- Expanded partnership with seqWell enhances PacBio's sequencing solutions by adding the LongPlex™ Multiplexing Kit, providing customers with a scalable and efficient sample preparation option.
- The LongPlex™ Multiplexing Kit is designed to streamline sample prep, reducing bottlenecks, and enabling rapid, high-quality data generation for large-scale genomic research.
- This collaboration demonstrates PacBio's commitment to flexibility, speed, and accuracy in meeting the needs of researchers across diverse fields, enhancing its competitive positioning in the genomics market.
- Global availability of the LongPlex™ Multiplexing Kit set for 2026 signifies strategic growth and the potential for increased market reach and customer engagement.
Potential Negatives
- The press release includes extensive forward-looking statements, which highlight risks and uncertainties related to product performance, potential collaboration challenges, and patent claims that could impact the company's future results.
- The statement regarding global availability of the LongPlex™ Multiplexing Kit in 2026 may indicate a lengthy timeline for accessibility, which could limit immediate competitive advantage.
- The press release employs vague language describing "potential product performance and quality issues," which could raise concerns among investors and customers about the reliability of new offerings.
FAQ
What is the LongPlex™ Multiplexing Kit?
The LongPlex™ Multiplexing Kit is a sample preparation solution for PacBio HiFi sequencing, designed for efficient DNA fragmentation and multiplexing.
How does LongPlex improve sample preparation?
LongPlex eliminates sample prep bottlenecks, allowing researchers to produce high-quality libraries quickly and cost-efficiently for large-scale projects.
What are the benefits of using the LongPlex Multiplexing Kit?
The kit supports rapid, high-throughput workflows, efficiently processing hundreds of samples with minimal hands-on time while maintaining data quality.
Which organizations are currently using LongPlex?
Organizations like Veil Genomics are utilizing LongPlex for population-scale efforts, enhancing their low-pass whole genome sequencing workflows.
Where can I find more information about LongPlex?
More details about the LongPlex™ Multiplexing Kit and its compatible workflows can be found on PacBio’s website at www.pacb.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- OENE MARK VAN (See Remarks) sold 26,836 shares for an estimated $35,181
- MICHELE FARMER (See Remarks) sold 5,195 shares for an estimated $5,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Hedge Fund Activity
We have seen 80 institutional investors add shares of $PACB stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EDMOND DE ROTHSCHILD HOLDING S.A. removed 8,488,980 shares (-38.8%) from their portfolio in Q2 2025, for an estimated $10,526,335
- MADRONE ADVISORS, LLC removed 6,629,699 shares (-28.3%) from their portfolio in Q2 2025, for an estimated $8,220,826
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,881,313 shares (-99.9%) from their portfolio in Q2 2025, for an estimated $6,052,828
- JACKSON SQUARE PARTNERS, LLC removed 2,767,258 shares (-83.3%) from their portfolio in Q2 2025, for an estimated $3,431,399
- AMIRAL GESTION added 2,733,290 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,389,279
- MORGAN STANLEY removed 2,539,962 shares (-75.3%) from their portfolio in Q2 2025, for an estimated $3,149,552
- POINT72 (DIFC) LTD added 2,459,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,049,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PACB Analyst Ratings
Wall Street analysts have issued reports on $PACB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $PACB, check out Quiver Quantitative's $PACB forecast page.
$PACB Price Targets
Multiple analysts have issued price targets for $PACB recently. We have seen 3 analysts offer price targets for $PACB in the last 6 months, with a median target of $1.5.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $1.5 on 08/11/2025
- Luke Sergott from Barclays set a target price of $1.5 on 06/25/2025
- Mason Carrico from Stephens & Co. set a target price of $1.8 on 05/15/2025
Full Release
MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and multiplexing workflow solutions. Under the new agreement, PacBio will distribute seqWell’s LongPlex™ Multiplexing Kit , a scalable, easy-to-use sample preparation solution designed for use with PacBio HiFi sequencing and optimized for efficient transposase-based DNA fragmentation and multiplexing. LongPlex removes sample prep bottlenecks, enabling researchers to produce high-quality libraries quickly, support current studies cost-efficiently, and power the next wave of population-scale research.
This collaboration expands the portfolio of workflow options available to PacBio customers, complementing PacBio’s highly accurate long-long read technology with an additional flexible, high-throughput sample prep solution. The LongPlex™ Multiplexing Kit uses tagmentation to simultaneously fragment and index DNA for up to hundreds of samples in a single run, making it ideal for large-scale screening and targeted resequencing efforts.
“Expanding our partnership with seqWell is part of our commitment to meet researchers where they are with the flexibility, speed, and accuracy they need,” said David Miller, Vice President of Global Marketing at PacBio. “By offering LongPlex alongside our existing workflows, we’re giving customers more choice across high-throughput applications, especially where rapid, economical data generation is essential.”
Organizations such as Veil Genomics are already demonstrating the value of LongPlex for population-scale efforts.
“At Veil, our goal is to democratize genomic insights through scalable, cost-effective data,” said Josh Clevenger, Ph.D., Co-founder of Veil Genomics. “The LongPlex™ Multiplexing Kit has allowed us to continue to develop our low-pass WGS workflow, supporting efficient DNA fragmentation and multiplexing that let us process thousands of samples without compromising data quality for downstream analysis.”
By supporting sample prep across low-pass WGS, plasmid sequencing, and microbial sequencing, LongPlex extends options for researchers working in diverse fields. Its streamlined indexed tagmentation workflow reduces hands-on time while maintaining the performance required for high-quality sequencing data.
“We’re proud to expand our collaboration with PacBio, bringing LongPlex™ to more labs worldwide,” said Dan Calvo, President and CEO of seqWell. “This agreement reflects a shared vision to accelerate discovery by making innovative, practical sample prep tools widely available to genomic researchers.”
The LongPlex™ Multiplexing Kit is available today, with global availability in 2026, adding a scalable sample prep option to PacBio’s portfolio of sequencing solutions.
For more information about the LongPlex™ Multiplexing Kit and compatible workflows, please visit www.pacb.com .
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About seqWell
seqWell creates scalable genomics technologies that simplify library preparation workflows and help scientists to unlock transformative discoveries with sequencing. seqWell offers a range of library prep products and tagmentation workflows designed to meet the throughput and cost demands of modern genomics applications including population-scale, short- and long-read sequencing initiatives. Learn more at www.seqwell.com or follow us on Linkedin .
About Veil Genomics
Veil Genomics is a precision genomics company dedicated to population-scale low-pass WGS and data-driven insights for health and agriculture. By combining innovative sequencing pipelines with powerful analytics, Veil delivers actionable genomic information to drive real-world impact.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, or quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, such as those in connection with seqWell’s LongPlex Multiplexing Kit, expanding sample prep and workflow options, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in new collaborations; the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8- K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts (PacBio)
Investors:
Media: [email protected]
